
Faron Pharmaceuticals H2 2023 - Entering a new phase

Redeye provides a research update on Faron Pharmaceuticals following the company's recent annual report, precarious financial situation, and clinical progress with lead candidate Bexmarilimab. With upcoming BEXMAB read-outs and a planned larger share issue ahead, we abstain from making any changes in our valuation for now.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Faron Pharmaceuticals H2 2023 - Entering a new phase](#)